Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
Dr. O'Connor delivered the following material as a poster at the 2003 American Society of Hematology meeting highlighting results from his work with bortezomib in the treatment of non-Hodgkin's and mantle cell lymphoma. A full publication of his results will appear later this year. Abstract #2346 appears in Blood, Volume 102, issue 11, November 16, 2003. The American Society of Hematology Poster Session "Lymphoma: Treatment and Supportive Care" took place on Sunday, December 7, 2003.
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Owen
O
O'Connor
John
J
Wright
Craig H
CH
Moskowitz
Jamie
J
Muzzy
Barbara
B
MacGregor-Cortelli
Paul
P
Hamlin
David
D
Straus
Elizabeth
E
Trehu
David P
DP
Schenkein
Andrew D
AD
Zelenetz
D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use*
D001897:Boronic Acids; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib